CPVT068
ITXi009-A
General
Cell Line |
|
| hPSCreg name | ITXi009-A |
| Cite as: | ITXi009-A (RRID:CVCL_B5QA) |
| Alternative name(s) |
CPVT068
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi007-A (NP0014-6, UKK007Ai) Donor's gene variants: RYR2, RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia UKKi007-B (NP0014-5) Donor's gene variants: RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia TAUi005-A (UTA.14511.CPVT) Donor's gene variants: RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia TAUi004-A (UTA.05208.CPVT) Donor's gene variants: RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia FAMRCi005-A (LMNA B4) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia FAMRCi005-B (LMNA B5) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia SCVIi073-A (SCVIi574C2) Donor's gene variants: titin, BAG cochaperone 3, BAG cochaperone 3 Donor diseases: Dilated Cardiomyopathy SCVIi074-A (SCVIi599C1) Donor's gene variants: BAG cochaperone 3 Donor diseases: Hypertrophic Cardiomyopathy FAMRCi006-A (LMNA T3) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy FAMRCi006-B (LMNA T4) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy ZJSHi001-A (ZJSHi-KCNB1) Donor's gene variants: KCNB1 Donor diseases: developmental and epileptic encephalopathy, 26 |
| Last update | 2nd February 2022 |
| User feedback | |
Provider |
|
| Generator | l’institut du thorax (ITX) |
| Derivation country | France |
External Databases |
|
| BioSamples | SAMEA11291308 |
| Cellosaurus | CVCL_B5QA |
| Wikidata | Q111733537 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | North-west European |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | First degree relatives were victim of unexplained sudden cardiac death |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Normal female karyotypes with no aneuploidies detected |
Donor Relations |
|
| All cell lines of this donor's relatives |
Has aunt:
|
External Databases (Donor) |
|
| BioSamples | SAMEA11291309 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | MESRI and CPP Ouest II |
| Approval number | Autorisation IE 2009-505(1) ; MESR n° DC-2011-1399; Autorisation CPP 46/11 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew XF
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: 33
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
|
Login to share your feedback, experiences or results with the research community.